{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:54:19Z","timestamp":1780595659559,"version":"3.54.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171982"],"award-info":[{"award-number":["82171982"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010882","name":"Tianjin Municipal Education Commission","doi-asserted-by":"publisher","award":["2018KJ060"],"award-info":[{"award-number":["2018KJ060"]}],"id":[{"id":"10.13039\/501100010882","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2020Y9101"],"award-info":[{"award-number":["2020Y9101"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020J05249"],"award-info":[{"award-number":["2020J05249"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2020GGA045"],"award-info":[{"award-number":["2020GGA045"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    The goal of this study was to report a fully automated radiosynthetic procedure of a novel tau tracer [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 and its safety, biodistribution, and dosimetry in healthy volunteers as well as the potential utility of [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 positron emission tomography (PET) in Alzheimer\u2019s disease (AD).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    The automated radiosynthesis of [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 was performed on a GE Tracerlab FX2 N module. For the biodistribution and dosimetry study, healthy volunteers underwent a series of PET scans acquired at 10, 60, 120, and 240 min post-injection. The biodistribution and safety were assessed. For the AD study, both AD and healthy controls (HCs) underwent dynamic [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 and static [\n                    <jats:sup>18<\/jats:sup>\n                    F]-FDG PET imaging. [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 binding was assessed quantitatively using standardized uptake value ratios (SUVRs) measured at different regions of interest (ROIs). [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 SUVRs were compared between the AD patients and HCs using the Mann\u2013Whitney\n                    <jats:italic>U<\/jats:italic>\n                    -test. In AD patients with all cortical ROIs, Spearman rank-correlation analysis was used to calculate the voxel-wise correlations between [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 and [\n                    <jats:sup>18<\/jats:sup>\n                    F]-FDG.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The automated radiosynthesis of [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 was finished within 45 min, with a radiochemical yield of 30 \u00b1 5% (\n                    <jats:italic>n<\/jats:italic>\n                    = 8, non-decay-corrected). The radiochemical purity was greater than 98%, and the specific activity was calculated to be 1,047 \u00b1 450 GBq\/\u03bcmol (\n                    <jats:italic>n<\/jats:italic>\n                    = 5), and [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 was stable\n                    <jats:italic>in vitro<\/jats:italic>\n                    . In the healthy volunteer study, no adverse effect was observed within 24\u00a0h post-injection, and no defluorination was observed\n                    <jats:italic>in vivo<\/jats:italic>\n                    . The radiotracer could pass through the blood\u2013brain barrier easily and was rapidly cleared from the circulation and excreted through the hepatic system. The whole-body mean effective dose was 15.3 \u00b1 0.3 \u03bcSv\/MBq. In AD patients, [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 accumulation was identified as involving the parietal, temporal, precuneus, posterior cingulate, and frontal lobes. No specific [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 cerebral uptake was identified in HCs. The SUVR of AD patients was significantly higher than that of HCs. No specific binding uptake was found in the choroid plexus, venous sinus, and white matter. A significant correlation was found between [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 binding and hypometabolism across neocortical regions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 could be synthesized automatically, and it showed favorable biodistribution and safety in humans. [\n                    <jats:sup>18<\/jats:sup>\n                    F]-S16 PET indicated a high image quality for imaging tau deposition in AD and distinguishing AD from HCs.\n                  <\/jats:p>","DOI":"10.3389\/fbioe.2021.812818","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T02:03:03Z","timestamp":1644458583000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [18F]-S16 in Healthy Volunteers and Its Application in Assessment of Tau Pathology in Alzheimer\u2019s Disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00401-014-1254-6","article-title":"A Novel In Vivo Model of Tau Propagation with Rapid and Progressive Neurofibrillary Tangle Pathology: the Pattern of Spread Is Determined by Connectivity, Not Proximity","volume":"127","author":"Ahmed","year":"2014","journal-title":"Acta Neuropathol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","article-title":"In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls","volume":"60","author":"Betthauser","year":"2018","journal-title":"J. Nucl. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"996","DOI":"10.2967\/jnumed.116.182980","article-title":"In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317","volume":"58","author":"Betthauser","year":"2017","journal-title":"J. Nucl. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/acn3.339","article-title":"Impact of Tau and Amyloid burden on Glucose Metabolism in Alzheimer's Disease","volume":"3","author":"Bischof","year":"2016","journal-title":"Ann. Clin. Transl Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer Disease-Associated Neurofibrillary Pathology Using Paraffin Sections and Immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0197-4580(97)00056-0","article-title":"Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories","volume":"18","author":"Braak","year":"1997","journal-title":"Neurobiol. Aging"},{"key":"B7","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/nen.0b013e318232a379","article-title":"Stages of the Pathologic Process in Alzheimer Disease: Age Categories from 1 to 100 Years","volume":"70","author":"Braak","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JAD-130098","article-title":"Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808","volume":"38","author":"Chien","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1007\/s00259-016-3363-z","article-title":"Imaging In-Vivo Tau Pathology in Alzheimer's Disease with THK5317 PET in a Multimodal Paradigm","volume":"43","author":"Chiotis","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24711","article-title":"In Vivo cortical Spreading Pattern of Tau and Amyloid in the Alzheimer Disease Spectrum","volume":"80","author":"Cho","year":"2016","journal-title":"Ann. Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11307-015-0924-7","article-title":"Human Radiation Dosimetry of [18F]AV-1451(T807) to Detect Tau Pathology","volume":"18","author":"Choi","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.parkreldis.2015.08.011","article-title":"Imaging Biomarkers in Tauopathies","volume":"22","author":"Dani","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1093\/brain\/awy188","article-title":"Microglial Activation Correlates In Vivo with Both Tau and Amyloid in Alzheimer's Disease","volume":"141","author":"Dani","year":"2018","journal-title":"Brain"},{"key":"B14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.neuron.2011.11.033","article-title":"Propagation of Tau Pathology in a Model of Early Alzheimer's Disease","volume":"73","author":"de Calignon","year":"2012","journal-title":"Neuron"},{"key":"B15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3233\/JAD-160316","article-title":"In Vivo Patterns of Tau Pathology, Amyloid-\u03b2 Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease","volume":"55","author":"Dronse","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awr038","article-title":"18F-THK523: a Novel In Vivo Tau Imaging Ligand for Alzheimer's Disease","volume":"134","author":"Fodero-Tavoletti","year":"2011","journal-title":"Brain"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1038\/s41467-019-12921-z","article-title":"Tau Deposition Is Associated with Functional Isolation of the hippocampus in Aging","volume":"10","author":"Harrison","year":"2019","journal-title":"Nat. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2967\/jnumed.114.139550","article-title":"Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology","volume":"55","author":"Hashimoto","year":"2014","journal-title":"J. Nucl. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.2967\/jnumed.116.189126","article-title":"Biodistribution and Radiation Dosimetry for the Tau Tracer 18F-THK-5351 in Healthy Human Subjects","volume":"58","author":"Hsiao","year":"2017","journal-title":"J. Nucl. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/wnl.0000000000002923","article-title":"A\/T\/N: An Unbiased Descriptive Classification Scheme for Alzheimer Disease Biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","article-title":"Longitudinal Tau PET in Ageing and Alzheimer's Disease","volume":"141","author":"Jack","year":"2018","journal-title":"Brain"},{"key":"B22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00401-015-1407-2","article-title":"PART, a Distinct Tauopathy, Different from Classical Sporadic Alzheimer Disease","volume":"129","author":"Jellinger","year":"2015","journal-title":"Acta Neuropathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00401-017-1681-2","article-title":"Tau Aggregation Influences Cognition and Hippocampal Atrophy in the Absence of Beta-Amyloid: a Clinico-Imaging-Pathological Study of Primary Age-Related Tauopathy (PART)","volume":"133","author":"Josephs","year":"2017","journal-title":"Acta Neuropathol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2967\/jnumed.115.160127","article-title":"PET Quantification of Tau Pathology in Human Brain with 11C-PBB3","volume":"56","author":"Kimura","year":"2015","journal-title":"J. Nucl. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11307-019-01367-w","article-title":"Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles","volume":"22","author":"Koole","year":"2020","journal-title":"Mol. Imaging Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ana.24844","article-title":"Pathological Correlations of [F-18]-AV-1451 Imaging in Non-alzheimer Tauopathies","volume":"81","author":"Marqui\u00e9","year":"2017","journal-title":"Ann. Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating Novel Tau Positron Emission Tomography Tracer [F-18]-AV-1451 (T807) on Postmortem Brain Tissue","volume":"78","author":"Marqui\u00e9","year":"2015","journal-title":"Ann. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mds.27603","article-title":"18 F\u2010AV\u20101451 Uptake Differs between Dementia with Lewy Bodies and Posterior Cortical Atrophy","volume":"34","author":"Nedelska","year":"2019","journal-title":"Mov Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2967\/jnumed.117.201632","article-title":"Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models","volume":"59","author":"Ni","year":"2018","journal-title":"J. Nucl. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ana.24321","article-title":"Tau, Amyloid, and Hypometabolism in a Patient with Posterior Cortical Atrophy","volume":"77","author":"Ossenkoppele","year":"2015","journal-title":"Ann. Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET Patterns Mirror Clinical and Neuroanatomical Variability in Alzheimer's Disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain"},{"key":"B33","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","article-title":"The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer's Disease","volume":"82","author":"Spires-Jones","year":"2014","journal-title":"Neuron"},{"key":"B34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0022-510x(70)90063-8","article-title":"Observations on the Brains of Demented Old People","volume":"11","author":"Tomlinson","year":"1970","journal-title":"J. Neurol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1021\/acs.jmedchem.6b00166","article-title":"Discovery of 6-(Fluoro-18f)-3-(1h-Pyrrolo[2,3-C]pyridin-1-Yl)isoquinolin-5-Amine ([18F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)","volume":"59","author":"Walji","year":"2016","journal-title":"J. Med. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11307-018-1219-6","article-title":"Spatial Patterns of Hypometabolism and Amyloid Deposition in Variants of Alzheimer's Disease Corresponding to Brain Networks: a Prospective Cohort Study","volume":"21","author":"Wang","year":"2019","journal-title":"Mol. Imaging Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jalz.2018.02.020","article-title":"Imaging Correlations of Tau, Amyloid, Metabolism, and Atrophy in Typical and Atypical Alzheimer's Disease","volume":"14","author":"Whitwell","year":"2018","journal-title":"Alzheimer's Demen."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/brain\/awab120","article-title":"Discriminatory Ability of Next-Generation Tau PET Tracers for Alzheimer's Disease","volume":"144","author":"Yap","year":"2021","journal-title":"Brain"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00259-013-2512-x","article-title":"Suggested Pathway to Assess Radiation Safety of 18F-Labeled PET Tracers for First-In-Human Studies","volume":"40","author":"Zanotti-Fregonara","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1021\/acs.molpharmaceut.0c01078","article-title":"Synthesis and Evaluation of Fluorine-18 Labeled 2-Phenylquinoxaline Derivatives as Potential Tau Imaging Agents","volume":"18","author":"Zhou","year":"2021","journal-title":"Mol. Pharmaceutics"}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2021.812818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T02:03:08Z","timestamp":1644458588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2021.812818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":40,"alternative-id":["10.3389\/fbioe.2021.812818"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2021.812818","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-958599\/v1","asserted-by":"object"}]},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"article-number":"812818"}}